E2F3 gene expression is a potential negative prognostic marker for localised and MYCN not‐amplified neuroblastoma: Results of in silico analysis of 786 samples
暂无分享,去创建一个
F. Zara | S. Parodi | A. Pezzolo | D. Cangelosi | S. Sorrentino | M. Ognibene | S. Zanardi | Davide Cangelosi
[1] M. Ohira,et al. Loss of p53 suppresses replication stress-induced DNA damage in ATRX-deficient neuroblastoma , 2021, Oncogenesis.
[2] F. Westermann,et al. Neuroblastoma—Telomere maintenance, deregulated signaling transduction and beyond , 2021, International journal of cancer.
[3] Hong Liu,et al. MiR-493-5p inhibits the malignant development of gliomas via suppressing E2F3-mediated dysfunctions of P53 and PI3K/AKT pathways , 2021, Clinical and Translational Oncology.
[4] Ting Ye,et al. Emerging Role of E2F Family in Cancer Stem Cells , 2021, Frontiers in Oncology.
[5] H. Saavedra,et al. E2F3 drives the epithelial-to-mesenchymal transition, cell invasion, and metastasis in breast cancer , 2021, Experimental biology and medicine.
[6] T. Kamijo,et al. How Do Telomere Abnormalities Regulate the Biology of Neuroblastoma? , 2021, Biomolecules.
[7] Zhaohui Xu,et al. An Update on the Potential Roles of E2F Family Members in Colorectal Cancer , 2021, Cancer management and research.
[8] J. Bertino,et al. Anti-Tumor Effects of a Penetratin Peptide Targeting Transcription of E2F-1, 2 and 3a Is Enhanced When Used in Combination with Pemetrexed or Cisplatin , 2021, Cancers.
[9] Jörg Otte,et al. MYCN Function in Neuroblastoma Development , 2021, Frontiers in Oncology.
[10] O. Delattre,et al. Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] M. Muselli,et al. Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming , 2020, Cancers.
[12] S. Parodi,et al. The Over-Expression of E2F3 Might Serve as Prognostic Marker for Neuroblastoma Patients with Stage 4S Disease , 2020, Diagnostics.
[13] Jo Lynne Rokita,et al. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma , 2020, Cancer Research.
[14] H. Yao,et al. The E2F family as potential biomarkers and therapeutic targets in colon cancer , 2020, PeerJ.
[15] X. Zou,et al. Regulation of E2F Transcription Factor 3 by microRNA-152 Modulates Gastric Cancer Invasion and Metastasis , 2020, Cancer management and research.
[16] M. Capasso,et al. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients , 2019, Genes, chromosomes & cancer.
[17] J. Johnsen,et al. Neuroblastoma—A Neural Crest Derived Embryonal Malignancy , 2019, Front. Mol. Neurosci..
[18] A. Di Cataldo,et al. Stage 4 s neuroblastoma: features, management and outcome of 268 cases from the Italian Neuroblastoma Registry , 2019, Italian Journal of Pediatrics.
[19] K. Ohtani,et al. Mitochondrial protein E2F3d, a distinctive E2F3 product, mediates hypoxia-induced mitophagy in cancer cells , 2019, Communications Biology.
[20] F. Westermann,et al. A mechanistic classification of clinical phenotypes in neuroblastoma , 2018, Science.
[21] O. Delattre,et al. Age-dependency of the prognostic impact of tumor genomics in localized resectable MYCN non-amplified neuroblastomas Report from the SIOPEN Biology Group on the LNESG Trials , 2018 .
[22] T. Hocking,et al. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients , 2018, Journal of the National Cancer Institute.
[23] Mariano J. Alvarez,et al. Cross-Cohort Analysis Identifies a TEAD4-MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma. , 2018, Cancer discovery.
[24] D. Rickman,et al. The Expanding World of N-MYC-Driven Tumors. , 2018, Cancer discovery.
[25] M. Rubin,et al. Differential impact of RB status on E2F1 reprogramming in human cancer , 2017, The Journal of clinical investigation.
[26] J. Rehg,et al. MYCN induces neuroblastoma in primary neural crest cells , 2017, Oncogene.
[27] Long-Bang Chen,et al. MiRNAs and E2F3: a complex network of reciprocal regulations in human cancers , 2017, Oncotarget.
[28] F. Purrello,et al. Altered expression of miRNAs and methylation of their promoters are correlated in neuroblastoma , 2016, Oncotarget.
[29] F. Berthold,et al. Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] E. Tokunaga,et al. The 1,2-Diaminocyclohexane Carrier Ligand in Oxaliplatin Induces p53-Dependent Transcriptional Repression of Factors Involved in Thymidylate Biosynthesis , 2015, Molecular Cancer Therapeutics.
[31] May D. Wang,et al. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction , 2015, Genome Biology.
[32] J. Shohet,et al. Neuroblastoma: molecular pathogenesis and therapy. , 2015, Annual review of medicine.
[33] A. Vicha,et al. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification , 2014, British Journal of Cancer.
[34] F. Berthold,et al. Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project , 2014, Pediatric blood & cancer.
[35] Roland Eils,et al. Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers , 2014, Clinical Cancer Research.
[36] O. Delattre,et al. Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN , 2014, PloS one.
[37] V. Pistoia,et al. Intratumoral diversity of telomere length in individual neuroblastoma tumors , 2014, Oncotarget.
[38] A Garaventa,et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. , 2013, European journal of cancer.
[39] Michael A. Dyer,et al. Neuroblastoma: developmental biology, cancer genomics and immunotherapy , 2013, Nature Reviews Cancer.
[40] Jinghui Zhang,et al. Association of age at diagnosis and genetic mutations in patients with neuroblastoma. , 2012, JAMA.
[41] T. McDonnell,et al. The RB-E2F1 pathway regulates autophagy. , 2010, Cancer research.
[42] Qiang Yu,et al. The E2F family and the role of E2F1 in apoptosis. , 2009, The international journal of biochemistry & cell biology.
[43] Gudrun Schleiermacher,et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Knowles,et al. Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification , 2008, Oncogene.
[46] R. Stallings,et al. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.
[47] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[48] C. Cooper,et al. Role of E2F3 expression in modulating cellular proliferation rate in human bladder and prostate cancer cells , 2007, Oncogene.
[49] A. Nicholson,et al. Nuclear overexpression of the E2F3 transcription factor in human lung cancer. , 2006, Lung cancer.
[50] David G Johnson,et al. Distinct and Overlapping Roles for E2F Family Members in Transcription, Proliferation and Apoptosis. , 2006, Current molecular medicine.
[51] Jing Xu,et al. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. , 2005, Journal of the National Cancer Institute.
[52] V. Gorgoulis,et al. Involvement of E2F transcription factor family in cancer. , 2005, European journal of cancer.
[53] K. Helin,et al. The E2F family: specific functions and overlapping interests , 2004, The EMBO journal.
[54] R. Wooster,et al. Amplification and overexpression of E2F3 in human bladder cancer , 2004, Oncogene.
[55] H. Shimada,et al. The International Neuroblastoma Pathology Classification. , 2003, Pathologica.
[56] W. Lutz,et al. E2F Proteins Regulate MYCN Expression in Neuroblastomas* , 2003, The Journal of Biological Chemistry.
[57] W. London,et al. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] P. V. Rao,et al. Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .
[59] K K Matthay,et al. The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.
[60] F. Berthold,et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.
[61] F. Speleman,et al. Neuroblastoma: A Tough Nut to Crack. , 2016, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[62] J. Maris,et al. Advances in the translational genomics of neuroblastoma: From improving risk stratification and revealing novel biology to identifying actionable genomic alterations , 2016, Cancer.